- Home
- FOXF vs NVCR Comparison
FOXF vs NVCR Comparison
Compare FOXF & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FOXF
- NVCR
- Stock Information
- Founded
- FOXF 2007
- NVCR 2000
- Country
- FOXF United States
- NVCR Switzerland
- Employees
- FOXF N/A
- NVCR N/A
- Industry
- FOXF Motor Vehicles
- NVCR Medical/Dental Instruments
- Sector
- FOXF Consumer Discretionary
- NVCR Health Care
- Exchange
- FOXF Nasdaq
- NVCR Nasdaq
- Market Cap
- FOXF N/A
- NVCR 1.9B
- IPO Year
- FOXF N/A
- NVCR 2015
- Fundamental
- Price
- FOXF $26.66
- NVCR $17.02
- Analyst Decision
- FOXF Buy
- NVCR Buy
- Analyst Count
- FOXF 7
- NVCR 7
- Target Price
- FOXF $36.43
- NVCR $32.43
- AVG Volume (30 Days)
- FOXF 519.4K
- NVCR 1.2M
- Earning Date
- FOXF 07-31-2025
- NVCR 07-24-2025
- Dividend Yield
- FOXF N/A
- NVCR N/A
- EPS Growth
- FOXF N/A
- NVCR N/A
- EPS
- FOXF N/A
- NVCR N/A
- Revenue
- FOXF $1,415,479,000.00
- NVCR $621,711,000.00
- Revenue This Year
- FOXF $5.17
- NVCR $5.44
- Revenue Next Year
- FOXF $6.34
- NVCR $9.05
- P/E Ratio
- FOXF N/A
- NVCR N/A
- Revenue Growth
- FOXF 1.26
- NVCR 18.27
- 52 Week Low
- FOXF $17.95
- NVCR $14.17
- 52 Week High
- FOXF $54.86
- NVCR $34.13
- Technical
- Relative Strength Index (RSI)
- FOXF 49.55
- NVCR 47.92
- Support Level
- FOXF $27.55
- NVCR $17.33
- Resistance Level
- FOXF $29.56
- NVCR $18.59
- Average True Range (ATR)
- FOXF 1.26
- NVCR 0.69
- MACD
- FOXF 0.01
- NVCR 0.01
- Stochastic Oscillator
- FOXF 43.58
- NVCR 31.44
About NVCR NovoCure Limited
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.